NZ515964A - A method for the prophylaxis and/or treatment of medical disorders - Google Patents

A method for the prophylaxis and/or treatment of medical disorders

Info

Publication number
NZ515964A
NZ515964A NZ515964A NZ51596400A NZ515964A NZ 515964 A NZ515964 A NZ 515964A NZ 515964 A NZ515964 A NZ 515964A NZ 51596400 A NZ51596400 A NZ 51596400A NZ 515964 A NZ515964 A NZ 515964A
Authority
NZ
New Zealand
Prior art keywords
seq
treatment
prophylaxis
nucleic acid
medical disorders
Prior art date
Application number
NZ515964A
Inventor
Christopher John Wraight
George Arthur Werther
Stephanie Ruth Dmondson
Original Assignee
Murdoch Childrens Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Murdoch Childrens Res Inst filed Critical Murdoch Childrens Res Inst
Publication of NZ515964A publication Critical patent/NZ515964A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Abstract

Use of a nucleic acid molecule selected from the group consisting of 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12); 5'- CACAGUUGCUGCAAG-3' (SEQ ID NO:13); 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14); 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15); 5'- GCCUUGGAGAUGAGC-3' (SEQ ID NO:16); 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17); 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18); 5'- CGGCAAGCUACACAG-3' (SEQ ID NO:19); 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical analogue of any one of said nucleic acid molecules as hereinbefore defined in the manufacture of a medicament for the treatment of a proliferative or inflammatory skin disorder or in a composition capable of inhibiting or otherwise reducing IGF- I mediated cell proliferation.
NZ515964A 1999-06-21 2000-06-21 A method for the prophylaxis and/or treatment of medical disorders NZ515964A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14034599P 1999-06-21 1999-06-21
PCT/AU2000/000693 WO2000078341A1 (en) 1999-06-21 2000-06-21 A method for the prophylaxis and/or treatment of medical disorders

Publications (1)

Publication Number Publication Date
NZ515964A true NZ515964A (en) 2004-03-26

Family

ID=22490818

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515964A NZ515964A (en) 1999-06-21 2000-06-21 A method for the prophylaxis and/or treatment of medical disorders

Country Status (6)

Country Link
EP (1) EP1191941A4 (en)
JP (1) JP2003502383A (en)
AU (1) AU768904B2 (en)
CA (1) CA2376284A1 (en)
NZ (1) NZ515964A (en)
WO (1) WO2000078341A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165196A1 (en) * 2001-05-07 2002-11-07 Eric Wickstrom Oligonucleotide inhibitors of cancer cell proliferation
US7396922B2 (en) * 2001-11-28 2008-07-08 Angiogenetics Sweden Ab Regulation of hypoxia-inducible gene expression with antisense Inhibitory PAS domain protein
ES2307942T3 (en) 2002-01-17 2008-12-01 The University Of British Columbia OLIGONUCLEOTID ANTISENTIDO BIESPECIFICOS INHIBITING IGFBP-2 AND IGFBP-5 AND METHODS OF USE.
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc Rna interference mediated inhibition of map kinase genes
JP4338527B2 (en) 2002-04-05 2009-10-07 サンタリス ファーマ アー／エス Oligomer compounds that regulate HIF-1α expression
EP2404928A1 (en) * 2003-07-02 2012-01-11 Verenium Corporation Glucanases, nucleic acids encoding them and methods for making and using them
JP2007527227A (en) * 2003-08-05 2007-09-27 アビ バイオファーマ， インコーポレイテッド Oligonucleotide analogues and methods for the treatment of flavivirus infections
CA2539727C (en) 2003-10-01 2016-11-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
ES2361325T3 (en) 2004-06-28 2011-06-16 The University Of Western Australia OLIGONUCLEÓTIDOS ANTISENTIDO TO INDUCE THE OMISSION OF EXON AND METHODS OF USE OF THE SAME.
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
AU2005304112B2 (en) 2004-11-09 2009-06-04 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
EP2366786A3 (en) 2005-05-05 2012-08-29 VALORISATION HSJ, Société en Commandite Cytokine receptor modulators and uses thereof
PT1966368E (en) * 2005-12-29 2012-11-02 Alcon Res Ltd Rnai-mediated inhibition of igf-1r for treatment of ocular angiogenesis
CA2655997A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
WO2008113773A2 (en) * 2007-03-16 2008-09-25 Biorigen S.R.L. Gene expression regulation technology and noncoding rnas for diagnosis and therapy
EP3133160B1 (en) 2008-10-24 2018-12-12 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
PL2396038T3 (en) * 2009-02-12 2016-05-31 Curna Inc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
JP2013500017A (en) * 2009-07-24 2013-01-07 カッパーアールエヌエー，インコーポレイテッド Treatment of sirtuin (SIRT) related diseases by blocking natural antisense transcripts to sirtuin (SIRT)
WO2011022606A2 (en) * 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
KR20230137491A (en) 2009-11-12 2023-10-04 더 유니버시티 오브 웨스턴 오스트레일리아 Antisense Molecules and Methods for Treating Pathologies
EP2802674B1 (en) 2012-01-11 2020-12-16 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of ikbkap splicing
CN110218727A (en) 2013-03-14 2019-09-10 萨勒普塔医疗公司 For treating the exon skipping composition of muscular dystrophy
US20140329762A1 (en) 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
NO344051B1 (en) * 2017-05-04 2019-08-26 Patogen As Novel virus in Fish and Method for detection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0726911B1 (en) * 1993-09-20 2002-10-30 Celtrix Pharmaceuticals, Inc. Treatment of hematologic disorders with a igf-1/igfbp-3 complex
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
AU692278B2 (en) * 1994-07-08 1998-06-04 Murdoch Childrens Research Institute, The A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
SE9501472D0 (en) * 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I

Also Published As

Publication number Publication date
EP1191941A4 (en) 2006-12-13
WO2000078341A1 (en) 2000-12-28
CA2376284A1 (en) 2000-12-28
JP2003502383A (en) 2003-01-21
EP1191941A1 (en) 2002-04-03
AU5202000A (en) 2001-01-09
AU768904B2 (en) 2004-01-08
WO2000078341A8 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
NZ515964A (en) A method for the prophylaxis and/or treatment of medical disorders
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
EP1158985A4 (en) OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP0939621A4 (en) Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
AU3368497A (en) Human dnase i hyperactive variants
WO2001072831A3 (en) Immunoregulator
ATE475716T1 (en) COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP1362600A4 (en) Pharmaceutical compositions containing decoy and method of using the same
PL1644504T3 (en) Factor vii or viia gla domain variants
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
DE69911401D1 (en) Immunoregulator
MY117918A (en) Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
IL162600A0 (en) Cc-chemokine mutants as cc-chemokine antagonists
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
EP1282641A4 (en) Human cervical cancer suppressor protein, polynucleotide encoding the protein, cell transformed with the polynucleotide and method for suppressing proliferation of cancer cell using the expression vector
TR200200987T2 (en) Substituted pyrroles for cancer treatment
PL321890A1 (en) Variants human dnase i
WO2001010382A3 (en) Compositions and methods related to claudin-7
UA36167A (en) Method for treating pancreatitis

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed